

**REMARKS**

This Amendment is responsive to the Office Action mailed May 22, 2008. By this Amendment, Applicants amend claims 1, 12, 16, 24, 35, and 42 and cancel claims 8-11, 13, and 34. Claims 1, 12, 16, 24, 35, 38, 42, 43, 48, 51, and 53 are pending. Claims 1, 12, 16, 24, 35, 42, 43, 48, 51, and 53 are under consideration. Claim 38 is withdrawn.

Reconsideration and withdrawal of the rejections made in the above-referenced Office Action are respectfully requested in view of the following amendments and remarks. Support for the amendments as filed can be found in the specification and claims as filed, e.g., original claims 1 and 24.

**Information Disclosure Statement**

Applicants thank the Examiner for acknowledgement of receipt of the Information Disclosure Statement filed March 3, 2008, and for consideration of all the documents listed therein.

**Claim Rejections – 35 U.S.C. § 112, First Paragraph**

The Office Action maintains the rejection of claim 16 under 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the enablement requirement. In particular, the Office Action asserts that the claim “still recites ‘antitumor agent’.”

In response, Applicants submit the instant claims are enabled and that the amendment submitted herewith addresses the instant rejection. Therefore, Applicants respectfully request withdrawal of the rejection under 35 U.S.C. § 112, first paragraph (enablement).

Claim Objections

The Office Action objects to claims 1, 8-13, 16, 24, 34, 35, 38, 42, 43, 48, 51 and 53 as allegedly containing non-elected subject matter. Applicants note that the claims have been amended and that further examination has been greatly simplified. Applicants therefore respectfully request that the Examiner rejoin the non-elected subject matter remaining in the pending claims.

The Office Action also objects to claim 42 as being an essential duplicate of claim 24. Applicants submit that the instant amendment addresses the objection to claim 42, and respectfully request withdrawal of the same.


Conclusion

In view of the foregoing, the Examiner is respectfully requested to reconsider and withdraw the rejection of record, and allow all the pending claims.

No additional fee is believed due at this time. If, however, any additional fee is necessary to ensure consideration of the submitted materials, the Patent and Trademark Office is hereby authorized to charge the same to Deposit Account No. 19-0089.

Should there be any questions, the Examiner is invited to contact the undersigned at the below listed telephone number.

Respectfully submitted,  
Chikara MURAKATA et al.



Bruce H. Bernstein  
Reg. No. 29,027

Stephen M. Roylance  
Reg. No. 31,296

August 22, 2008  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191